Summary Tissue specimens from 150 patients with localised prostatic carcinomas and 116 patients with prostatic carcinomas with distant metastases were analysed for histological grade (WHO and Gleason) and immunoreactivity for prostate acid phosphatase (PAP), prostate-specific antigen (PSA), neurone-specific enolase (NSE), p53 protein, c-erbB-2 protein, cytokeratins (AEI/AE3) and vimentin. After stratification for the presence or absence of distant metastases, multivariate regression analysis revealed that WHO grading was the most powerful independent prognosticator, followed by age and prostate acid phosphatase expression. There was a trend towards reduced survival with decreasing prostate-specific antigen reactivity. The Gleason system showed poor prognostic ability. The analysis predicted reduced survival in the presence of extensive neurone-specific enolase reactivity, mostly because of one case of small-cell carcinoma.
Prostate cancer exhibits great variation in biological behaviour (Gleason et al., 1974; Murphy et al., 1982; Epstein et al., 1986; Johansson et al., 1989; Smith et al., 1991; Whitmore et al., 1991) . Any parameter that reflects the malignant potential of an individual tumour may be of decisive importance for the clinician. Histological grade and extension of the disease are at present the discriminating prognosticators most frequently used.
In recent years, several additional biological tumour markers have been presented. Immunohistochemical demonstration of neuroendocrine features (di Sant'Agnese & de Mesy Jensen, 1987; Cohen et al., 1991) , c-erbB-2 protein (Gullick et al., 1991; Reilly et al., 1991; Hale et al., 1992) , p53 protein (Porter et al., 1992) , prostate acid phosphatase (PAP) (Sakai et al., 1991) , prostate-specific antigen (PSA) (Hammond et al., 1989; Bazinet et al., 1992) and vimentin (Leong et al., 1988) has been related to tumour prognosis. However, at present there is no general agreement concerning the best combination of prognostic factors.
The aim of this study was to examine the prognostic significance of each of the above-mentioned factors in tissue sections (histological grade, cellular atypia, PSA, PAP, cerbB-2 protein, p53 protein, vimentin and cytokeratins) together with age and metastatic status in an unselected series of patients to determine the most significant prognosticators. (Hsu et al., 1981) . After removal of paraffin, the sections were treated for 30 min with 0.3% hydrogen peroxide in methanol to block endogenous peroxidase, followed by 20 min incubation with normal goat serum diluted 1:75 in 0.01 M phosphatebuffered saline (pH 7.4) containing 5% bovine serum albumin (BSA) to eliminate non-specific staining. The sections were then incubated at 4°C overnight using the antisera listed in Table II (PAP, PSA, AEI/AE3, NSE, p53 protein, c-erbB-2 protein, vimentin), followed by 30 min incubation with ABC (10 g ml avidin and 2.5 tg ml-' biotin-labelled peroxidase). The tissues were stained for 5 min with 0.05% 3'3-diaminobenzidine-tetrahydrochloride freshly prepared in 0.05% Tris buffer (pH 7.6) containing 0.01% hydrogen peroxide and then counterstained with haematoxylin, dehydrated and mounted. Localisation of the immunostaining product in relation to cellular morphology was noted. Only nuclear p53 staining products and membranous c-erbB-2 staining products were considered as positive. The fraction of immunoreactive tumour cells was semiquantitatively graded from 0 to + + + in each section. Control studies included relevant positive controls and all showed specific immunostaining. Negative controls included substitution of primary antiserum with relevant normal nonspecific serum diluted 1:300 or incubation with antisera absorbed with their homologous antigens prior to testing, and all controls were negative.
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The relationships between the different variables were measured by the Spearman correlation coefficient statistical package (Hintze, 1992 , and all were core biopsies. We also observed significant correlations between each of the grading systems and cellular atypia (Table IV) .
Most tumours expressed strong immunoreactivity (+ +/ + + +) for PAP (98.1%), PSA (79.7%) and AE1/AE3 (85.0%), as shown in Table V . In well-differentiated tumours PAP, PSA and AE1/AE3 immunoreactivity was seen in the majority of cells (PAP, 100%; PSA, 85%; AE1/AE3, 87%). Among intermediate-grade tumours, some were strongly positive in most cells; others showed a focal immunoreactivity. Tumours that were negative for the above-mentioned factors were poorly differentiated (PAP, 100%; PSA, 58%; AE1/AE3, 78%) and expressed the greatest degree of cell heterogeneity. The three PAP-negative tumours were also negative for PSA: two were WHO grade 3 and one WHO grade 4. As shown in Table IV Figure 1 . The death hazard for each factor was in accordance with the results of the univariate survival analysis stratified for M category (Table VI) .
The analysis of each factor stratified by the presence or absence of distant metastases is shown in There has been a complete follow-up of all patients with respect to mortality and cause of death. Although the general validity of death certificates may be discussed, the number of errors are known to be low for malignant tumours (Glattre & Blix, 1980) . Cancer treatment is often recorded in The Norwegian Cancer Registry but is not an obligatory parameter.
The statistical analyses compare the relative ability of each variable to reflect survival, regardless of treatment. The study did not aim to predict length of survival, only the relative death hazard of each of the investigated parameters, and we suppose that treatment options have no selective influence on the investigated variables in this respect. Furthermore, from the literature there is little evidence that any of the given therapies (surgical or medical castration) has any major impact on survival.
For prostate cancer the most important prognostic parameter is the presence or absence of metastases. In this study we selected only tumours which were either confined to the prostate (MO) or had distant metastases (Ml) . The N category remained unknown in the majority of our patients as pelvic lymphadenectomy was not performed routinely in patients with clinically localised disease.
The demonstration of distant metastases varied during the 15 years of the study. The majority of patients had a skeletal radiograph taken. Bone scanning was performed routinely only in the second half of the study period. Elevated serum PAP alone was usually not recorded as an expression of distant metastases. The various parameters were analysed separately in the Cox regression model, which was stratified by metastatic stage (MO/Mi). As shown in Table III , some factors were either positive (PAP, AE1/AE3) or negative (c-erbB-2, vimentin) in most tumours. This implies that such factors, although resulting in statistically significant correlations, may be of less importance for the majority of patients because of their poor discriminating power.
Tumour grading is an attempt to predict the behaviour of tumours on the basis of their morphology. More (1986) noticed that, compared with the complicated Gleason system, the less complicated grading systems resulted in the highest inter-observer reproducibility. Our data from the uniand multivariate Cox regression model confirm that the WHO system (Mostofi system) is superior to the Gleason system in predicting survival, which is in agreement with Gallee et al. (1990) and Humphrey et al. (1991) . Like Schroeder et al. (1985) , our univariate analysis demonstrates that cellular atypia predicts survival. Although we found significant correlations between the Gleason and the WHO systems and cellular atypia, the WHO system added prognostic information beyond that provided by the Gleason system and by cellular atypia in the stepwise Cox regression model. However, whereas most recent reports presenting good prognostication using the Gleason system have been performed on prostatectomy specimens, our series is based on pretreatment biopsies characterised by cauterisation artefacts (TUR-P specimens) and scanty material (core biopsies). As in our recent study of hormone-resistant prostatic carcinomas (Berner et al., 1993) , we noticed some undergrading by the Gleason system in core biopsies.
Prostate acid phosphatase and PSA are produced both in benign and in malignant prostatic tissue and are widely used as tumour markers (Stamey et al., 1987) . In contrast to benign epithelium, most reports on prostatic cancer tissue demonstrate heterogeneity in immunostaining of PAP and PSA and an apparent correlation between variation in stainability and tumour grade (Epstein & Eggleston, 1984; Sesterhenn et al., 1985; Feiner & Gonzales, 1986) , which was also observed in our study. Like Sesterhenn et al. (1985) and Feiner and Gonzales (1986) Mesy Jensen, 1987; Ro et al., 1987; Cohen et al., 1991) , and it has been suggested that the demonstration of neuroendocrine features is an indicator of poor prognosis. Unlike di Sant'Agnese and de Mesy Jensen (1987) and Cohen et al. (1991) , who used a series of different neuroendocrine markers, we applied only one monoclonal antibody raised against NSE, which may explain the lower scoring rate in our series (18%). Furthermore, neuroendocrine differentiation is mostly focal (Cohen et al., 1991) and small tissue specimens such as core biopsies may be inadequate in demonstrating such features. Thirty-eight per cent of the specimens in our study were core biopsies. Extensive NSE staining (+ + +) predicted poor outcome in the multivariate analysis. However, this was largely due to one core biopsy which histologically was a small-cell carcinoma. The 95% confidence interval was wide (Table VII) , and the general significance of this result should therefore be viewed with caution. On the other hand, it has been reported ) that small-cell carcinomas in the prostate frequently demonstrate neuroendocrine features. In a study of 20 small-cell carcinomas of the prostate, Tetu et al. (1987) reported a median survival of only 5 months. The patient in our study died 4 months after diagnosis of his prostate cancer.
The published data on any potential association between age and survival of prostate cancer are conflicting, and there is no general support in the literature for the concept that younger patients may have particularly aggressive tumours. Kant et al. (1992) reported a significant decrease in the relative 5 year survival in prostate cancer patients 75 years of age and older, and Partin et al. (1992) in a study of localised prostate cancer found age to be a significant and independent parameter by multivariate analysis. The findings of Kent et al. (1992) and Partin et al. (1992) of some relation between age and prognosis are in agreement with ours. However, this observation must be interpreted cautiously because of possible bias due to less intensive cancer treatment in elderly patients. p53 mutations and p53 protein accumulation appear to be one of the most common features in several human neoplasms (Levine et al., 1991; Porter et al., 1992) . In contrast to the short half-life, wild-type p53 protein present in normal tissues and undetectable immunohistochemically, the mutant form can be detected by immunohistochemical techniques. The biological significance of p53 overexpression is not yet established, but most authors agree that p53 protein expression occurs relatively late in neoplastic transformation. In prostate cancer nuclear p53 protein accumulation has been correlated with histological grade (Mellon et al., 1992) , tumour progression (Berner et al., 1993) and DNA ploidy (Visakorpi et al., 1992) . Van Veldhuizen et al. (1993) recently reported a predominant cytoplasmic staining pattern in 79% of a series of prostatic carcinomas. However, their negative controls were insufficient and their observations thus seem questionable. In our study only 17% of prostatic carcinomas demonstrated nuclear p53 protein accumulation. There was no correlation with survival or grade, although we found a weak trend in the univariate analysis indicating lower survival by increasing p53 protein accumulation.
Cytokeratins are a complex group of polypeptides that form cytoskeletal intermediate filaments specific for epithelial cells. Cytokeratin expression is found in both benign and malignant prostatic epithelium. The AEl/AE3 antibodies used in this study recognise high and low molecular weight cytokeratins (Woodcock-Mitchell et al., 1982) . High molecular weight cytokeratins react in basal cells and may be a helpful criterion for the diagnosis of well-differentiated prostatic carcinomas (Sherwood et al., 1991) . Like PAP and PSA, cytokeratins are markers for cell maturity. Like others (Feiner & Gonzales, 1986; Berner et al., 1993) we found reduced or absent expression of AE1/AE3 in poorly differentiated tumours.
Vimentin is a marker of mesenchymal tissues. However, coexpression of cytokeratin and vimentin has been found in normal prostatic epithelium (Leong et Leong et al. (1988) found positive vimentin staining in 83% of prostatic adenocarcinomas. In our study only 5% of the carcinomas were vimentin positive and the variable was not useful in the prediction of survival.
Although c-erbB-2 protein reactivity has been noticed in many different tumours, only a few studies have been performed on prostatic cancer tissue (McCann et al., 1990; Ware et al., 1991; Mellon et al., 1992) . Both Ware et al. (1991) and Mellon et al. (1992) used fresh material and found c-erbB-2 protein expression in 71% and in 21%, respectively, while McCann et al. (1990) did not observe c-erbB-2 protein expression in formalin-fixed tissue. Ware et al. (1991) also compared fresh and formalin-fixed tissue, and found that formalin fixation significantly reduced the c-erbB-2 protein immunoreactivity, which may explain the rather low c-erbB-2 protein reactivity (1.5%) in our series.
In summary, although modern immunohistochemistry certainly yields exciting insight into the development of prostate cancer, for the routine clinician the longer established variables such as patient's age, WHO grade, presence of distant metastases and PAP stainability give the most important prognostic information in the majority of patients. The fact that WHO grading was superior to Gleason grading and that the impact of PAP stainability exceeds that of PSA stainability needs further investigation.
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